Examples of 'actriib' in a sentence
Meaning of "actriib"
actriib is not a recognized English word. It may be a misspelling or a specialized term used in a specific context
How to use "actriib" in a sentence
Basic
Advanced
actriib
Variants derived from ActRIIB and uses therefor.
The activin binding polypeptide may be an ActRIIa polypeptide or an ActRIIb polypeptide.
Inhibits ActRIIB signaling in a cell.
Variants derived from ActRIIB.
Portion of ActRIIB corresponds.
This sequence is also poorly conserved between ActRIIb and ActRIIa.
An immunogenic portion of an ActRIIB polypeptide can be administered in the presence of adjuvant.
Inhibitors of ActRII receptors include ActRIIA inhibitors and ActRIIB inhibitors.
The variant ActRIIB fusion protein of the invention may be produced as a homodimer.
Preferably such an antibody binds to the ligand binding domain of ActRIIB.
Many of the ligands that bind to ActRIIB are also highly conserved.
The disclosure identifies functionally active portions and variants of ActRIIB.
Any of the above variant ActRIIB fusion proteins may be produced as a homodimer.
A variety of screening assays may be used to evaluate ActRIIB polypeptide variants.
Compositions comprising the ActRIIB fusión polypeptides described herein are administered in therapeutically effective amounts.
See also
Also disclosed herein are methods for making a soluble ActRIIB polypeptide.
Another targeted delivery system for ActRIIB polynucleotides is a colloidal dispersion system.
The compounds can be identified by their ability to interact with an ActRIIB polypeptide.
Preferred for therapeutic delivery of ActRIIB polynucleotide sequences is the use of targeted liposomes.
The following examples illustrate this approach to defining an active ActRIIB variant.
The leader sequence may be a native ActRIIB leader sequence or a heterologous leader sequence.
The methods comprise contacting the cell with a soluble ActRIIB polypeptide.
The variant ActRIIB protein of the invention may be a fusion protein further comprising a heterologous portion.
The subject compounds may be identified by their ability to interact with an ActRIIB polypeptide.
The ActRIIB fusión polypeptides described herein may also be tagged with a detectable or functional label.
A pharmaceutical preparation comprising the variant ActRIIB protein for use of any preceding claim.
The assays below are described for ActRIIa but can be performed analogously for ActRIIb.
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy.
The following methods were used for expressing and purifying the stabilized ActRIIB polypeptides.
Mutations were generated in ActRIIB extracellular domain by PCR mutagenesis.
ActRIIB polypeptides may also be useful in the treatment of osteoporosis.
Overview The present invention relates generally to ActRIIB polypeptides.
An Fc fusión protein having the ActRIIB extracellular sequence disclosed by Hilden et al.
ActRII receptors include ActRIIA inhibitors and ActRIIB inhibitors.
ActRIIB or ActRIIB ligands are involved in the regulation of many critical biological processes.
Overview The present invention relates generally to nucleic acids encoding ActRIIB polypeptides.
ActRIIB polypeptides of the invention may also be useful in the treatment of osteoporosis.
CDNA is obtained from libraries prepared from mRNA isolated from various tissues that express ActRIIB.
ActRIIb Polypeptides The present invention relates to ActRIIb polypeptides.
In other embodiments, an ActRII receptor inhibitor is specific to ActRIIB.
ActRIIB variants described herein are GDF Traps unless otherwise stated.
In other embodiments, an ActRII receptor inhibitor preferentially inhibits ActRIIB.
ActRIIb is the high affinity receptor for both myostatin and activin B.
A pharmaceutical preparation comprising the variant ActRIIB protein of claim 1.
The human ActRIIb precursor protein sequence is as follows,.
In certain aspects, the present invention relates to ActRIIB polypeptides.
The human ActRIIb precursor protein sequence is was follows,.
Accordingly, disclosed are methods of producing the subject ActRIIB polypeptides.
Further, ActRIIB polypeptides may be used in prevention / reversal of osteoarthritis.
In specific embodiments, the extracellular domain or portion thereof of ActRIIB is soluble.
